How High Will Brown Forman Stock Go?
On the surface, Brown‑Forman (NYSE: BF.B) is having an unremarkable year.…
Sell
39
BHST Quote, Financials, Valuation and Earnings
Last price:
$6.9000
Seasonality move
:
-4.02%
Day range:
$6.8628 - $7.1424
52-week range:
$4.6600 - $7.8600
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.27x
P/B ratio:
84.68x
Volume:
3.8K
Avg. volume:
8.7K
1-year change:
12.89%
Market cap:
$119.9M
Revenue:
$25.2M
EPS (TTM):
-$0.50
Analysts' Opinion
-
Consensus RatingBioHarvest Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.7500, BioHarvest Sciences has an estimated upside of 113.15% from its current price of $6.9200.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.0000 representing 100% downside risk from its current price of $6.9200.
Fair Value
-
According to the consensus of 1 analyst, BioHarvest Sciences has 113.15% upside to fair value with a price target of $14.7500 per share.
BHST vs. S&P 500
-
Over the past 5 trading days, BioHarvest Sciences has underperformed the S&P 500 by -4.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioHarvest Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioHarvest Sciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioHarvest Sciences reported revenues of $7.9M.
Earnings Growth
-
BioHarvest Sciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioHarvest Sciences reported earnings per share of -$0.13.
Enterprise value:
124M
EV / Invested capital:
--
Price / LTM sales:
4.27x
EV / EBIT:
--
EV / Revenue:
4.48x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-12.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$15.5M
Return On Assets:
-36.94%
Net Income Margin (TTM):
-31.3%
Return On Equity:
-534.46%
Return On Invested Capital:
-145.22%
Operating Margin:
-21.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $7M | $15.9M | $27.7M | $5.3M | $7.9M | |
| Gross Profit | $1.8M | $7.8M | $15.5M | $3M | $4.6M | |
| Operating Income | -$10.5M | -$8.9M | -$7.3M | -$1.4M | -$1.7M | |
| EBITDA | -$7.7M | -$10.6M | -$5.5M | -$1.2M | -$1.3M | |
| Diluted EPS | -$0.76 | -$1.35 | -$0.50 | -$0.48 | -$0.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.6M | $3.3M | $3.2M | $7.6M | $9.6M | |
| Total Assets | $9.9M | $8M | $8.5M | $12.9M | $26.6M | |
| Current Liabilities | $7M | $2.3M | $10M | $13.3M | $18.9M | |
| Total Liabilities | $12.7M | $6.7M | $13.6M | $16.1M | $27.5M | |
| Total Equity | -$2.8M | $1.3M | -$5.2M | -$3.2M | -$876K | |
| Total Debt | -- | -- | $6.1M | $8M | $7.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.4M | -$8.4M | -$6.5M | -$1.6M | -$1.4M | |
| Cash From Investing | -$1.2M | -$1.3M | -$3.5M | -$222K | -$680K | |
| Cash From Financing | $8.7M | $12.8M | $10M | -$116K | $3.1M | |
| Free Cash Flow | -$9.6M | -$9.8M | -$9.8M | -$1.8M | -$2.1M | |
BHST
Sector
Market Cap
$119.9M
$244.4M
Price % of 52-Week High
88.04%
75%
Dividend Yield
0%
0%
Shareholder Yield
--
2.89%
1-Year Price Total Return
12.89%
-10.63%
Beta (5-Year)
1.222
0.377
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.1052
200-day SMA
Buy
Level
$5.9796
Bollinger Bands (100)
Buy
Level
5.7101 - 6.9701
Chaikin Money Flow
Sell
Level
-76.4K
20-day SMA
Sell
Level
$6.9652
Relative Strength Index (RSI14)
Sell
Level
49.1893
ADX Line
Sell
Level
21.5236
Williams %R
Neutral
Level
-63.4218
50-day SMA
Buy
Level
$6.7817
MACD (12, 26)
Buy
Level
0.0693
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
416.9K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0627)
Sell
CA Score
(Annual)
Level (-5.6587)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (7.7794)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Stock Forecast FAQ
In the current month, BHST has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHST average analyst price target in the past 3 months is $14.7500.
-
Where Will BioHarvest Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioHarvest Sciences share price will rise to $14.7500 per share over the next 12 months.
-
What Do Analysts Say About BioHarvest Sciences?
Analysts are divided on their view about BioHarvest Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioHarvest Sciences is a Sell and believe this share price will drop from its current level to $12.0000.
-
What Is BioHarvest Sciences's Price Target?
The price target for BioHarvest Sciences over the next 1-year time period is forecast to be $14.7500 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioHarvest Sciences is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BHST?
You can purchase shares of BioHarvest Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioHarvest Sciences shares.
-
What Is The BioHarvest Sciences Share Price Today?
BioHarvest Sciences was last trading at $6.9000 per share. This represents the most recent stock quote for BioHarvest Sciences. Yesterday, BioHarvest Sciences closed at $6.9200 per share.
-
How To Buy BioHarvest Sciences Stock Online?
In order to purchase BioHarvest Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Flying Under the Radar?
Bloom Energy (NYSE:BE) manufactures scalable fuel cells for providing on-site…
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
55
TLN alert for Jul 19
Talen Energy [TLN] is up 24.44% over the past day.
Sell
48
CRSP alert for Jul 19
CRISPR Therapeutics AG [CRSP] is up 18.22% over the past day.
Buy
83
SOC alert for Jul 19
Sable Offshore [SOC] is up 11.86% over the past day.
